Apyx Medical gets FDA 510(k) clearance for Renuvion dermal resurfacing handpiece

Apyx Medical Corp

Clearance for treatment of moderate to severe wrinkles, limited to Fitzpatrick skin types I–III.
Addressable market of ~200,000 wrinkle reduction procedures annually in the U.S.
Renuvion Dermal Handpiece indicated for specific dermal resurfacing procedures.
Limited launch planned for Q3 2022; full commercialization targeted by end of 2022.
CEO calls it 'one of the most important achievements' in the U.S. cosmetic surgery strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.